Despite muted Q3 performance, higher input costs and uncertainty over the Vivo joint venture, Dixon Technologies' valuation factors in multiple headwinds, with brokerages divided on outlook ...

BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.

Arch Biopartners is developing next-generation drug candidates that target IL-32, a cytokine implicated in diabetic kidney disease as described in Dr. Chun’s new publication. The goal is to produce a ...

Super Bowl 60 is underway, and fans in the stands at Levi's Stadium paid a pretty penny to watch the Patriots face the Seahawks.

As China's new drug R&D enters the "deep waters" of homogeneous competition, the path for followers has become increasingly crowded. Target congestion, rising costs, and intensifying global races have ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Dräger’s Engineered Solutions division has launched the Breathguard 2500, a rugged, bespoke gas detection system developed in response to a requirement from Rheinmetall Landsysteme for use in confined ...

With this latest order, Maersk’s forward orderbook now stands at 33 vessels, of which four are expected to be delivered before the end of 2026. The newbuild programme forms part of the company’s ...